The analysis argues retatrutide is still unapproved, so the year-end price rides on Mounjaro and Zepbound, which made up about 65% of last quarter's revenue.
Recap by typeshit. Full story at FinanceFeeds.
Beauty companies are reportedly exploring products aimed at facial volume loss in people who have lost weight on GLP-1 drugs.
A short Fox16 social clip points to GLP-1 users shifting how they drink when they go out, with the full story linked in the station's bio.
A Facebook share points to shifting drinking habits in pubs and bars as more people take GLP-1 medications, with the full story linked.
Food Dive reports the Atkins brand is shifting its pitch toward lapsed GLP-1 users, a growing group food companies are now chasing.
Roy writes for people on Ozempic or Wegovy worried about later effects, pointing to big trials that tallied side effects.
Doctors report two patients who developed perianal abscesses while on tirzepatide. A case report, not proof the drug caused them.
Loading…